Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930653 · ClinicalTrials.gov registry record · Phase 2
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
A Phase 2 study of Sezary Syndrome and Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 3
- Study locations
NCT04930653 is a Phase 2 study of Sezary Syndrome and Primary Cutaneous T-Cell Non-Hodgkin Lymphoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 34 participants, below the 80-participant average among 13 other Sezary Syndrome trials with a reported enrollment target (57% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04930653, a Phase 2 study of Sezary Syndrome and Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- BIOLOGICAL Mogamulizumab
- PROCEDURE Extracorporeal Photopheresis
Study Locations (3)
Arizona
- Mayo Clinic - Scottsdale
California
- City of Hope Medical Center - Duarte
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2022-10-19 |
| Est. Completion | 2028-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04930653
The ClinicalTrials.gov registry entry for NCT04930653 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 80-participant average among 13 other Sezary Syndrome trials with a reported enrollment target (57% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Sezary Syndrome appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04930653 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04930653 about?
NCT04930653 is a clinical study titled "Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma". This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a wide...
What is the current status of trial NCT04930653?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2022-10-19. Estimated completion is 2028-06-15.
What conditions does trial NCT04930653 study?
This clinical trial studies the following conditions: Sezary Syndrome, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Folliculotropic Mycosis Fungoides, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8.
What interventions are being tested in trial NCT04930653?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Mogamulizumab (BIOLOGICAL), Extracorporeal Photopheresis (PROCEDURE).
Who is sponsoring clinical trial NCT04930653?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04930653 being conducted?
This trial has 3 study locations across Arizona, California, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sezary Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
RECRUITING · Phase 2
-
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
RECRUITING · Phase 2
-
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
-
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
RECRUITING
-
Extracorporeal Photopheresis in Sezary Syndrome
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.